Trial Profile
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs JNJ 63709178 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 30 Aug 2021 Status changed from recruiting to completed.
- 25 Feb 2021 Planned End Date changed from 1 Oct 2022 to 26 Oct 2022.
- 25 Feb 2021 Planned primary completion date changed from 1 May 2022 to 23 May 2022.